Browse the corpus

This activity provides clinicians with a comprehensive understanding of apraxia of lid opening (ALO), a rare disorder characterized by difficulty initiating eyelid elevation despite normal oculomotor function. ALO primarily results from disruptions in neural networks that coordinate voluntary eyelid movement, rather than from muscle weakness or structural abnormalities. Commonly associated with neurodegenerative diseases such as Parkinson disease, ALO can also occur in other basal ganglia disorders and frontal lobe lesions. Clinicians gain insight into the neurological mechanisms, clinical presentation, diagnostic criteria, and differential diagnosis of ALO. The course highlights both pharmacological and nonpharmacological management strategies, emphasizing evidence-based practices and emerging treatments. Collaborative decision-making within an interprofessional team is emphasized, as it optimizes patient outcomes by ensuring a holistic approach to care that addresses both the neurological and functional aspects of the condition. Objectives: Apply knowledge of the pathophysiology of apraxia of lid opening to provide optimal care for affected patients. Implement the methods or techniques used to accurately evaluate and diagnose patients with apraxia of lid opening. Assess the evidenced-based management options available for treating apraxia of lid opening. Collaborate with an interprofessional team to advance the care, outcomes, and quality of life for patients affected by apraxia of lid opening. Access free multiple choice questions on this topic.

Apraxia of lid opening (ALO), also referred to as apraxia of eyelid opening, is a relatively uncommon disorder characterized by bilateral difficulty initiating eyelid elevation despite normal levator palpebrae superioris function and intact oculomotor innervation. Affected patients are unable to voluntarily reopen their eyes in the absence of primary muscular or neuromuscular abnormalities, often despite sustained contraction of the frontalis muscle. The term is somewhat of a misnomer, as the condition rarely represents true apraxia.[1] ALO is distinct from blepharospasm, in which involuntary orbicularis oculi contraction forces eyelid closure, and from ptosis, which reflects eyelid droop due to muscle weakness or mechanical factors.[2] Although ALO may occur as an isolated phenomenon, it is more commonly associated with underlying neurologic disease.[3] Max Heinrich Lewandowsky first described ALO in 1907 in his essay "Über Apraxie des Lidschlusses." Subsequent early reports were limited, including cases described by Schilder in 1927 and Riese in 1930, with additional series reported by Goldstein and Cogan in 1965.[4] ALO is often underrecognized or misdiagnosed due to its clinical subtlety and lack of pathognomonic findings. In addition to its association with neurodegenerative disorders, ALO has also been reported in patients with focal dystonias, structural brain lesions, and metabolic or toxic encephalopathies. Neuroimaging studies have suggested abnormalities within the basal ganglia–thalamocortical circuits, which play a crucial role in the initiation and coordination of voluntary movements. Functional imaging techniques such as positron emission tomography and functional magnetic resonance imaging have demonstrated altered activity in the supplementary motor area and frontal cortex in affected individuals. These findings further support the concept that ALO represents a disorder of motor planning and execution rather than a primary muscular dysfunction.[5][6]

In addition to its association with neurodegenerative disorders, ALO has also been reported in patients with focal dystonias, structural brain lesions, and metabolic or toxic encephalopathies. Neuroimaging studies have suggested abnormalities within the basal ganglia–thalamocortical circuits, which play a crucial role in the initiation and coordination of voluntary movements. Functional imaging techniques such as positron emission tomography and functional magnetic resonance imaging have demonstrated altered activity in the supplementary motor area and frontal cortex in affected individuals. These findings further support the concept that ALO represents a disorder of motor planning and execution rather than a primary muscular dysfunction.[5][6] ALO frequently coexists with blepharospasm as part of the blepharospasm-apraxia syndrome, where patients exhibit involuntary eyelid closure followed by difficulty reopening the eyelids. This combination can significantly impair visual function and quality of life, particularly in older patients with Parkinsonian syndromes. The prevalence of ALO among patients with Parkinson disease has been reported to range between 2% and 6%, although higher rates have been described in advanced stages of the disease and in those receiving dopaminergic therapy.[7] From an anatomical standpoint, eyelid opening requires coordinated activation of the levator palpebrae superioris muscle and simultaneous inhibition of the orbicularis oculi muscle. This process is mediated through complex supranuclear pathways involving the basal ganglia, brainstem reticular formation, and cortical motor areas. Disruption of these inhibitory pathways may result in persistent orbicularis activity or failure of levator activation, leading to the characteristic inability to initiate eyelid opening seen in ALO.[8] Clinically, patients often describe episodes where they are aware of their inability to open their eyes despite attempting to do so. These episodes may last from seconds to minutes and can be temporarily relieved by sensory tricks such as touching the eyelids, lifting the brows, or manually elevating them. Such maneuvers, often referred to as “geste antagoniste,” are commonly observed in dystonic disorders and may reflect temporary modulation of abnormal neural circuits.[9][10]

Clinically, patients often describe episodes where they are aware of their inability to open their eyes despite attempting to do so. These episodes may last from seconds to minutes and can be temporarily relieved by sensory tricks such as touching the eyelids, lifting the brows, or manually elevating them. Such maneuvers, often referred to as “geste antagoniste,” are commonly observed in dystonic disorders and may reflect temporary modulation of abnormal neural circuits.[9][10] The natural history of ALO varies depending on the underlying etiology. In idiopathic cases, symptoms may remain stable or fluctuate over time. However, when associated with progressive neurological conditions such as Parkinson disease or progressive supranuclear palsy, ALO may worsen as the underlying disease advances. Early recognition is therefore essential, as appropriate management of the underlying neurological disorder may reduce symptom severity and improve functional outcomes.[11][12] Although ALO is considered uncommon, it may be underrecognized in clinical practice due to its overlapping features with other eyelid disorders. Increased awareness among ophthalmologists, neurologists, and movement disorder specialists is essential to ensure timely diagnosis and appropriate management. Continued research into the neurophysiological mechanisms underlying ALO may help clarify its pathogenesis and lead to more targeted therapeutic approaches.[13]

In many patients, apraxia of lid opening (ALO) develops as part of a broader neurological disorder affecting motor planning and execution (see Table 1). Dysfunction of basal ganglia circuits, particularly the connections between the globus pallidus, thalamus, and supplementary motor cortex, is believed to play a central role in the development of ALO. Disruption of these pathways interferes with the coordinated inhibition of the orbicularis oculi muscle and activation of the levator palpebrae superioris muscle required for voluntary eyelid opening.[14] Neurodegenerative diseases are among the most frequently reported systemic associations. ALO is commonly observed in disorders such as Parkinson disease, progressive supranuclear palsy (PSP), corticobasal degeneration, and multiple system atrophy. In these conditions, degeneration of basal ganglia structures leads to impaired initiation of voluntary movements, including eyelid opening. In particular, ALO is considered a characteristic feature of PSP and may assist clinicians in differentiating it from other Parkinsonian syndromes.[15] Additional neurodegenerative and movement disorders reported in association with ALO include Huntington disease, dystonia-related Parkinsonism, motor neuron diseases, and Shy-Drager syndrome. Structural lesions of the central nervous system (CNS) may also lead to ALO. Tumors, traumatic brain injuries, demyelinating plaques, or vascular insults involving the frontal lobes, basal ganglia, or brainstem can disrupt neural pathways responsible for eyelid movement. Case reports have described ALO in association with lesions of the medial frontal cortex and the upper brainstem, highlighting the importance of supranuclear control mechanisms.[16] Vascular etiologies, including stroke affecting these regions, represent an important subset of structural causes.[17] Drug-induced ALO has been reported with medications that influence dopaminergic pathways. Dopamine antagonists, antipsychotic agents, and certain mood stabilizers may trigger dystonic reactions or interfere with basal ganglia function, leading to impaired eyelid opening. Similarly, exposure to neurotoxins affecting dopaminergic neurons has been implicated in rare cases.[18] Reported agents include lithium, sulpiride, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.[19]

Drug-induced ALO has been reported with medications that influence dopaminergic pathways. Dopamine antagonists, antipsychotic agents, and certain mood stabilizers may trigger dystonic reactions or interfere with basal ganglia function, leading to impaired eyelid opening. Similarly, exposure to neurotoxins affecting dopaminergic neurons has been implicated in rare cases.[18] Reported agents include lithium, sulpiride, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.[19] Infectious, metabolic, autoimmune, and toxic systemic conditions may also contribute to ALO through effects on CNS function. CNS infections, including viral encephalitis, bacterial meningitis, and prion diseases, have been associated with ALO.[20] Metabolic disorders and toxic exposures, including environmental toxins and heavy metals, may disrupt neural pathways involved in eyelid movement.[21][22] Autoimmune conditions affecting the CNS, such as multiple sclerosis or autoimmune encephalitis, have also been reported in association with ALO.[21][23] In addition to neurological causes, ocular and periocular conditions may contribute to symptoms that mimic or exacerbate ALO. Chronic ocular surface irritation, photophobia, or severe blepharospasm may lead to secondary difficulty opening the eyelids. Differentiating these conditions from true ALO is essential because the underlying pathophysiology and management strategies differ significantly.[24] Associated ocular conditions include infectious and inflammatory processes such as keratitis, blepharitis, dacryocystitis, and conjunctivitis, as well as autoimmune conditions such as keratoconjunctivitis sicca (eg, from Sjögren disease).[19] Mechanical and eyelid structural abnormalities, including ptosis and dermatochalasis, may also present with impaired eyelid opening and should be distinguished from ALO.[25][26] Although most cases occur secondary to neurological disease or focal dystonia, truly idiopathic cases of ALO have also been described. Idiopathic focal dystonia remains one of the most commonly reported underlying etiologies. In such patients, no identifiable neurological or structural cause is found despite thorough clinical and radiological evaluation. These cases are believed to represent a primary dysfunction of eyelid motor control circuits.[27] Table Table 1. Etiological Classification of Apraxia of Lid Opening.

Although most cases occur secondary to neurological disease or focal dystonia, truly idiopathic cases of ALO have also been described. Idiopathic focal dystonia remains one of the most commonly reported underlying etiologies. In such patients, no identifiable neurological or structural cause is found despite thorough clinical and radiological evaluation. These cases are believed to represent a primary dysfunction of eyelid motor control circuits.[27] Table Table 1. Etiological Classification of Apraxia of Lid Opening. ALO, apraxia of lid opening; CNS, central nervous system; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PSP, progressive supranuclear palsy

ALO is considered an uncommon neurological phenomenon, and its precise epidemiological burden remains difficult to quantify because it frequently occurs secondary to other neurological disorders such as Parkinson disease, progressive supranuclear palsy (PSP), or benign essential blepharospasm (see Table 2). Consequently, many epidemiological studies report ALO as part of the broader spectrum of eyelid dystonias rather than as a distinct condition (see Image. Epidemiology of Apraxia of Lid Opening).[15] Much of the available epidemiologic data are therefore extrapolated from studies of blepharospasm and related focal dystonias. ALO most commonly affects middle-aged and older individuals, typically presenting in the fifth to seventh decades of life, paralleling the age distribution of the neurodegenerative diseases with which it is frequently associated. This finding is consistent with epidemiologic data from benign essential blepharospasm, which demonstrate a peak incidence between 50 and 60 years of age.[28] Cases occurring in younger patients are rare and are usually linked to structural brain lesions, genetic disorders, or secondary dystonic syndromes.[16] Sex distribution studies indicate a slight female predominance, particularly when ALO occurs in association with benign essential blepharospasm or focal dystonia. This sex bias may reflect hormonal influences, differences in health-seeking behavior, or the higher prevalence of dystonia in women observed in several epidemiological studies.[24] Similarly, blepharospasm has been reported to occur more frequently in women (0.12%) than in men (0.07%).[28] Geographically, most epidemiological data originate from North America, Europe, and East Asia, where movement disorder registries and neuro-ophthalmology clinics have reported higher recognition rates. However, the true prevalence is likely underestimated worldwide because ALO is frequently misdiagnosed as ptosis, blepharospasm, or functional eyelid disorders. Increased awareness among ophthalmologists and neurologists has improved diagnostic accuracy in recent years.[6]

Geographically, most epidemiological data originate from North America, Europe, and East Asia, where movement disorder registries and neuro-ophthalmology clinics have reported higher recognition rates. However, the true prevalence is likely underestimated worldwide because ALO is frequently misdiagnosed as ptosis, blepharospasm, or functional eyelid disorders. Increased awareness among ophthalmologists and neurologists has improved diagnostic accuracy in recent years.[6] Patients with neurodegenerative disorders represent the largest identifiable subgroup. In Parkinson disease, ALO has been reported in approximately 2% to 6% of patients, whereas in PSP, the prevalence may be significantly higher. In addition, patients with blepharospasm may develop secondary ALO as part of blepharospasm-apraxia syndrome, which can significantly impair visual function and quality of life.[29] ALO may also progress over time, and within months to several years, the condition can result in substantial functional impairment, including visual disability and reduced independence. Occupational and environmental factors may also contribute indirectly to the epidemiology of eyelid movement disorders. Chronic ocular surface irritation, prolonged screen exposure, and environmental stressors may exacerbate underlying dystonic tendencies. These factors may partly explain the higher prevalence of eyelid dystonias observed in urban populations.[30] Increased risk has also been associated with certain comorbid conditions, including dyslipidemia, parasomnias, psychiatric disorders (eg, depression, anxiety, and obsessive-compulsive disorder), dry eye-related diseases (idiopathic or associated with Sjögren syndrome), and, to a lesser extent, Parkinson disease and rosacea.[31] Table Table 2. Epidemiological Characteristics of Apraxia of Lid Opening.

Apraxia of lid opening (ALO) is a disorder characterized by difficulty initiating lid elevation despite normal voluntary and reflex blinking. The pathophysiology of ALO is not entirely understood, but several mechanisms are thought to contribute to the condition (see Table 3). These mechanisms largely reflect dysfunction within corticothalamic, basal ganglia, and cranial nerve circuits involved in eyelid control, consistent with impairment of supranuclear motor pathways (see Image. Neural Mechanisms of Apraxia of Lid Opening).[32] Basal ganglia dysfunction: The basal ganglia play a critical role in the initiation and control of movement. In ALO, dysfunction within the basal ganglia circuitry, particularly in pathways involving the globus pallidus, is considered a significant factor. Nigrostriatal pathways may project to premotor regions responsible for eyelid coordination, further supporting a role for basal ganglia output in eyelid motor control.[32] This dysfunction can result from degenerative diseases, structural lesions, or neurochemical imbalances.[33] Supranuclear inhibition: ALO is thought to result from a failure to inhibit the tonic activity of the orbicularis oculi muscle, which closes the eyelids. Usually, voluntary lid opening involves a complex neural network that includes supranuclear pathways. Disruption of these pathways can impair the ability to overcome the orbicularis oculi's tonic contraction, making lid elevation difficult.[25] Levodopa sensitivity: Evidence suggests that ALO may be responsive to levodopa treatment in some cases, particularly when associated with Parkinson disease. This responsiveness implies a possible involvement of dopaminergic pathways in the pathophysiology of ALO.[34] At the biochemical level, abnormal dopamine neurotransmission likely contributes to disordered blinking and eyelid muscle activation.[35] Frontal lobe function: The frontal lobe, particularly the prefrontal cortex, is involved in planning and executing voluntary movements, including eyelid opening. Damage or dysfunction in this area can impair the ability to initiate lid opening, as seen in ALO.[36] Neuroimaging and electrophysiological studies have implicated both motor and nonmotor regions of the frontal lobe, supporting the concept of ALO as a disorder of motor intention in which the willed action does not translate into effective movement.[32]

Frontal lobe function: The frontal lobe, particularly the prefrontal cortex, is involved in planning and executing voluntary movements, including eyelid opening. Damage or dysfunction in this area can impair the ability to initiate lid opening, as seen in ALO.[36] Neuroimaging and electrophysiological studies have implicated both motor and nonmotor regions of the frontal lobe, supporting the concept of ALO as a disorder of motor intention in which the willed action does not translate into effective movement.[32] Abnormal blink reflex modulation: ALO may also be related to abnormalities in the blink reflex and its modulation. The reflex should be inhibited during voluntary lid opening, but this inhibition might be compromised in ALO.[37] Structures involved in the trigeminal blink reflex arc (including sensorimotor cortical regions, the substantia nigra pars reticulata, and brainstem motor nuclei) have been implicated in this process.[32] Sensorimotor integration: ALO can be associated with disruption of sensorimotor integration, the process by which the brain integrates sensory feedback with motor commands to produce smooth, coordinated movements.[38] Neurotransmitter imbalance: An imbalance in various neurotransmitters, including dopamine, may contribute to ALO, with changes in the cholinergic, serotonergic, and gamma-aminobutyric acid-ergic systems.[35] Neuromuscular anomalies: While not a primary factor, eyelid neuromuscular anomalies can contribute to difficulty opening the lid, especially when coexisting blepharospasm or ptosis is present.[25] These anomalies represent secondary contributors rather than primary pathophysiologic mechanisms.[35] Psychogenic factors: Although ALO is primarily a neurologic disorder, psychogenic factors have been considered in some cases, particularly when no clear neurologic cause can be identified.[39] Medication effects: Certain medications, especially those with neuromuscular blocking properties, can induce or exacerbate ALO. Understanding the adverse-effect profile of such medications is important for the clinical assessment of the condition.[40]

Psychogenic factors: Although ALO is primarily a neurologic disorder, psychogenic factors have been considered in some cases, particularly when no clear neurologic cause can be identified.[39] Medication effects: Certain medications, especially those with neuromuscular blocking properties, can induce or exacerbate ALO. Understanding the adverse-effect profile of such medications is important for the clinical assessment of the condition.[40] The combination of these factors results in the clinical presentation of ALO, in which patients are unable to open their eyelids at will despite having the necessary muscular function. Due to the disorder's complexity and overlap with other movement disorders, the exact pathophysiological mechanisms may vary between patients, and further research is needed to fully understand this condition. Table Table 3. Key Pathophysiological Mechanisms in Apraxia of Lid Opening.

Although ALO is primarily considered a functional neurological disorder rather than a structural muscular pathology, histopathological findings may be observed in the central nervous system structures involved in eyelid motor control, particularly when ALO occurs secondary to neurodegenerative diseases (see Table 4).[41] Postmortem studies and neuropathological analyses in such patients often reveal abnormalities in the basal ganglia, brainstem nuclei, and frontal lobes, particularly the prefrontal cortex, all of which are key components of the neural circuitry regulating voluntary eyelid movement (see Image. Histopathological Changes in Apraxia of Lid Opening).[30][42] Importantly, ALO does not typically demonstrate primary histopathological abnormalities within the eyelid musculature itself, as the disorder reflects impaired motor control rather than intrinsic muscle disease.[25] In patients with Parkinson disease, histopathology frequently demonstrates loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by Lewy body deposition composed of α-synuclein aggregates. These changes disrupt the nigrostriatal pathway, impairing basal ganglia modulation of voluntary movement, including eyelid opening.[15] Similar findings may be observed in other neurodegenerative conditions associated with ALO, in which neuronal loss and protein aggregation contribute to dysfunction of motor planning circuits.[43] Also, in progressive supranuclear palsy, neuropathological examinations reveal tau-positive neurofibrillary tangles and neuronal loss in the basal ganglia, subthalamic nucleus, and brainstem, particularly in midbrain structures responsible for ocular and eyelid movement control.[44] These changes are often accompanied by gliosis and degeneration within basal ganglia circuits, further impairing supranuclear control of voluntary movement.[33] These findings contribute to disruptions in motor planning and initiation pathways, which are central to the development of ALO in affected patients.

Also, in progressive supranuclear palsy, neuropathological examinations reveal tau-positive neurofibrillary tangles and neuronal loss in the basal ganglia, subthalamic nucleus, and brainstem, particularly in midbrain structures responsible for ocular and eyelid movement control.[44] These changes are often accompanied by gliosis and degeneration within basal ganglia circuits, further impairing supranuclear control of voluntary movement.[33] These findings contribute to disruptions in motor planning and initiation pathways, which are central to the development of ALO in affected patients. Microscopic alterations may also include reactive gliosis, neuronal loss, and synaptic dysfunction within the cortico-basal ganglia-thalamic circuits, which are critical for coordinating voluntary motor initiation. Alterations in synaptic density or number within these circuits have also been proposed, although such changes are typically identifiable only through specialized ultrastructural or molecular studies.[45] Although these findings are not specific to ALO, they support the hypothesis that the disorder arises from disruption of higher-order motor planning pathways rather than intrinsic eyelid muscle pathology.[30] Additional involvement of brainstem nuclei, which contribute to reflexive and automatic eyelid movements, has also been described in some cases.[46] Advanced molecular studies have suggested that dysregulation of dopaminergic, gamma-aminobutyric acid-ergic, and cholinergic neurotransmitter systems may further contribute to abnormal neural excitability and impaired motor control within these circuits. These neurochemical alterations are not typically identifiable on routine histopathological examination but may be demonstrated through specialized molecular or functional studies.[47] Consequently, histopathological findings in ALO often reflect the underlying neurological disorder rather than the eyelid disorder itself.[18] Table Table 4. Histopathological Findings Associated With Apraxia of Lid Opening. ALO, apraxia of lid opening; PSP, progressive supranuclear palsy

A careful clinical history is essential to distinguish ALO from other eyelid movement disorders (see Image. Clinical Assessment Pathway for Apraxia of Lid Opening). Patients often describe episodes in which they are unable to initiate eyelid opening after voluntary closure, despite preserved consciousness and normal ocular sensation. Symptoms most commonly occur immediately after voluntary eye closure or blinking and may be accompanied by a subjective sensation of periorbital contraction. Patients may also notice the symptoms upon awakening or after periods of sustained eye closure. The symptoms may fluctuate throughout the day and are frequently exacerbated by fatigue, emotional stress, or prolonged visual tasks such as reading or computer use. Some patients report transient improvement with tactile stimulation of the eyelid or brow (eg, geste antagoniste), or they may employ compensatory maneuvers such as manually lifting the eyelids, exaggerated facial movements, or neck extension, reflecting the abnormal sensorimotor integration.[27][29][48] Functional impairment is often significant. Patients may experience temporary functional blindness, particularly during activities requiring sustained attention, such as driving, walking outdoors, or performing fine visual tasks, especially when these activities involve shifting or refocusing the gaze.[15] This intermittent inability to open the eyelids can substantially affect independence and quality of life. In severe cases, patients may avoid social interaction or occupational activities because of embarrassment or disability caused by repeated episodes.[13] A thorough history should also assess symptom onset and progression, which is typically gradual, as well as potential triggers and risk factors such as medications, prior neurologic disease, or ocular conditions. Symptoms of underlying neurological disorders, such as Parkinson disease or various forms of dystonia, may be present, manifesting as tremors, muscle stiffness, or abnormal movements. A history of exposure to dopamine antagonists, neuroleptics, or other medications affecting basal ganglia function may provide important diagnostic clues. Stress and intense concentration have been known to worsen the condition, whereas periods of relaxation and spontaneous blinking might provide transient relief.[49]

A thorough history should also assess symptom onset and progression, which is typically gradual, as well as potential triggers and risk factors such as medications, prior neurologic disease, or ocular conditions. Symptoms of underlying neurological disorders, such as Parkinson disease or various forms of dystonia, may be present, manifesting as tremors, muscle stiffness, or abnormal movements. A history of exposure to dopamine antagonists, neuroleptics, or other medications affecting basal ganglia function may provide important diagnostic clues. Stress and intense concentration have been known to worsen the condition, whereas periods of relaxation and spontaneous blinking might provide transient relief.[49] During the physical examination, clinicians should carefully observe eyelid dynamics during blinking and attempted voluntary opening. A key clinical feature is failure of levator palpebrae activation immediately after blink closure, despite normal muscle strength when the eyelids are manually elevated. Electromyographic studies have demonstrated persistent orbicularis oculi activity during attempted eyelid opening, suggesting impaired inhibition of eyelid-closing muscles.[24] Patients may exhibit a characteristic "staring" appearance with infrequent blinking, a narrowed palpebral fissure, and compensatory frontalis overactivity, resulting in forehead wrinkling. An external evaluation of the eyelids and facial muscles is essential to assess for eyebrow and eyelid ptosis, dermatochalasis, and spasms of the orbicularis oculi, procerus, and corrugator muscles. Importantly, levator function and voluntary blink strength are preserved, helping distinguish ALO from true ptosis or primary muscle weakness.[50]

Patients may exhibit a characteristic "staring" appearance with infrequent blinking, a narrowed palpebral fissure, and compensatory frontalis overactivity, resulting in forehead wrinkling. An external evaluation of the eyelids and facial muscles is essential to assess for eyebrow and eyelid ptosis, dermatochalasis, and spasms of the orbicularis oculi, procerus, and corrugator muscles. Importantly, levator function and voluntary blink strength are preserved, helping distinguish ALO from true ptosis or primary muscle weakness.[50] Neurologic examination may reveal associated features depending on the underlying etiology and plays a critical role in differentiating ALO from other conditions that mimic its presentation, such as ptosis due to myasthenia gravis or mechanical eyelid obstruction. In patients with Parkinson disease or other basal ganglia disorders, signs such as bradykinesia, rigidity, resting tremor, or postural instability may be present. In contrast, individuals with isolated ALO may demonstrate no other neurologic abnormalities, making diagnosis dependent primarily on clinical observation.[16] Assessment of mental status, language skills, and other cranial nerve functions may be useful when central causes are suspected.[50] Because ALO may mimic several other ocular conditions, clinicians should systematically evaluate for mechanical, neuromuscular, and neurologic causes of eyelid dysfunction. Diagnostic workup may include neuroimaging, electromyography, or neurological consultation when secondary etiologies are suspected. A focused ophthalmologic examination is essential and may help identify alternative or contributing ocular pathology. Clinicians should assess visual acuity, visual fields, intraocular pressure, pupillary responses, and extraocular movements and should perform both a slit-lamp examination and a dilated fundoscopic evaluation.[15] Accurate differentiation is essential because treatment strategies vary significantly depending on the underlying mechanism (see Table 6).[51] Table 6. Key History and Physical Examination Findings in Apraxia of Lid Opening Table Clinical Domain Findings

ALO is primarily a clinical diagnosis, and careful assessment of the patient’s history and physical examination remains the cornerstone of evaluation (see Image. Diagnostic Approach to Apraxia of Lid Opening). Patients typically present with difficulty initiating voluntary eyelid opening despite preserved levator muscle function. A detailed ocular and neurological history should explore symptom onset, duration, progression, triggering factors (eg, fatigue or stress), and associated neurological symptoms. The diagnostic criteria described by Defazio and Berardelli are commonly used to identify dystonia-related eyelid disorders and include characteristic features such as bilateral eyelid involvement, stereotypical spasms, high resting blink frequency, inability to voluntarily suppress eyelid closure, and partial relief with sensory tricks (geste antagoniste).[16] These criteria, originally developed for blepharospasm, have demonstrated high diagnostic utility, with reported sensitivity of approximately 93% and specificity of 90% in distinguishing dystonic eyelid disorders (see Table 7).[52] Although no specific laboratory test confirms ALO, diagnostic investigations are often performed to exclude secondary causes or associated neurological disorders. Laboratory evaluation may include serum and cerebrospinal fluid panels to assess for systemic autoimmune, infectious, or metabolic etiologies.[53] When myasthenia gravis is part of the differential, acetylcholine receptor antibody testing, single-fiber electromyography, ice-pack testing, or edrophonium (eg, Tensilon) testing may be useful.[24][54] A comprehensive neurological examination is essential to evaluate for conditions frequently associated with ALO, including Parkinson disease, dystonia, or progressive supranuclear palsy. Neurophysiological testing, such as electromyography of the orbicularis oculi and levator palpebrae superioris muscles, can provide supportive evidence of impaired coordination between these opposing muscles. Such studies are helpful in differentiating dystonic eyelid disorders from neuromuscular or myogenic conditions.[27][55]

A comprehensive neurological examination is essential to evaluate for conditions frequently associated with ALO, including Parkinson disease, dystonia, or progressive supranuclear palsy. Neurophysiological testing, such as electromyography of the orbicularis oculi and levator palpebrae superioris muscles, can provide supportive evidence of impaired coordination between these opposing muscles. Such studies are helpful in differentiating dystonic eyelid disorders from neuromuscular or myogenic conditions.[27][55] Neuroimaging is not required to diagnose ALO but may be indicated to rule out structural brain lesions affecting motor control pathways, including the basal ganglia, brainstem, or frontal cortex. Magnetic resonance imaging of the brain with or without contrast is the preferred imaging modality when central nervous system pathology is suspected (eg, stroke, tumor, or demyelinating disease).[13] Computed tomography may also be used in selected cases, particularly when acute intracranial pathology is a concern. Because ALO is rare, specific national or international guidelines dedicated solely to its evaluation are limited. Clinicians, therefore, often follow evaluation frameworks recommended for movement disorders and focal dystonias, which emphasize comprehensive clinical assessment, targeted investigations to exclude alternative diagnoses, and multidisciplinary collaboration among ophthalmologists, neurologists, and neuro-ophthalmologists.[29] Given the overlap with other eyelid and movement disorders, a tailored, patient-specific approach is recommended to ensure accurate diagnosis and appropriate management.[56] Table Table 7. Diagnostic Evaluation in Apraxia of Lid Opening. ACh, acetylcholine; CT, computed tomography; MRI, magnetic resonance imaging

Managing ALO requires a multidisciplinary, stepwise approach, particularly because the disorder is frequently associated with underlying neurological conditions (see Image. Stepwise Treatment Algorithm for Apraxia of Lid Opening). The primary therapeutic goal is to reduce abnormal orbicularis oculi activity and facilitate voluntary eyelid opening while simultaneously addressing any associated systemic or neurological disease. Treatment selection should be tailored to the individual patient, with consideration of disease severity, underlying etiology, comorbid conditions, and response to prior interventions (see Table 8).[15] Botulinum toxin injections remain the most widely accepted and effective therapy, particularly when ALO is associated with blepharospasm or dystonic eyelid closure.[57][58] The toxin works by inhibiting acetylcholine release at the neuromuscular junction, thereby reducing involuntary contraction of the orbicularis oculi muscle and allowing the levator palpebrae superioris to elevate the eyelid more effectively.[13] Injections are typically administered to the pretarsal orbicularis oculi muscle in a targeted pattern to reduce spasm frequency and facilitate eyelid opening.[59][60] Pharmacologic therapy aimed at enhancing dopaminergic transmission may be particularly beneficial in patients with secondary ALO associated with Parkinson disease or other extrapyramidal disorders. For such patients, optimization of systemic neurological therapy may significantly improve symptoms. Adjustments in dopaminergic medications, including levodopa or dopamine agonists, have shown variable success in restoring motor coordination within the basal ganglia circuits responsible for eyelid opening.[13][58] For patients who do not respond adequately to medical therapy, surgical options may be considered. Orbicularis oculi myectomy, levator advancement procedures (eg, aponeurotic ptosis repair), blepharoplasty, and frontalis sling surgery have been described as treatment options in severe refractory cases.[16] These procedures aim to reduce the mechanical resistance to eyelid opening and facilitate alternative mechanisms of eyelid elevation.[24]

Pharmacologic therapy aimed at enhancing dopaminergic transmission may be particularly beneficial in patients with secondary ALO associated with Parkinson disease or other extrapyramidal disorders. For such patients, optimization of systemic neurological therapy may significantly improve symptoms. Adjustments in dopaminergic medications, including levodopa or dopamine agonists, have shown variable success in restoring motor coordination within the basal ganglia circuits responsible for eyelid opening.[13][58] For patients who do not respond adequately to medical therapy, surgical options may be considered. Orbicularis oculi myectomy, levator advancement procedures (eg, aponeurotic ptosis repair), blepharoplasty, and frontalis sling surgery have been described as treatment options in severe refractory cases.[16] These procedures aim to reduce the mechanical resistance to eyelid opening and facilitate alternative mechanisms of eyelid elevation.[24] Rehabilitation strategies may also play a supportive role. Behavioral therapy, eyelid physiotherapy, and biofeedback techniques may help patients improve voluntary motor control and adapt to their symptoms.[61] Nonpharmacologic strategies, such as sensory tricks (geste antagoniste) involving tactile stimulation of the eyelid or brow, may provide transient symptomatic relief in some patients.[61] Additionally, addressing psychological stressors and improving patient education can enhance treatment adherence and overall quality of life.[44] Because ALO is rare and heterogeneous, specific national or international guidelines dedicated solely to ALO management do not yet exist. Therefore, treatment decisions are largely guided by case series, expert consensus, and management principles derived from dystonia and blepharospasm guidelines. Collaborative care involving ophthalmologists, neurologists, and movement-disorder specialists is essential to achieve optimal outcomes.[6][62] Table Table 8. Treatment Modalities for Apraxia of Lid Opening.

ALO is a clinical diagnosis that must be distinguished from a range of neurologic, neuromuscular, structural, and functional conditions associated with impaired eyelid opening (see Table 9). These disorders share overlapping clinical features but differ in underlying mechanisms and management. The following differential diagnosis is organized by major etiologic categories, along with key clinical mimics, to facilitate systematic evaluation. Idiopathic (primary dystonia) Benign essential blepharospasm: Involuntary eyelid closure that may be associated with sensory symptoms such as eye-burning pain, keratoconjunctivitis sicca, photophobia, and relief with sensory tricks (geste antagoniste) [63][64] Meige syndrome: Combination of blepharospasm with oromandibular and cervical dystonia Brueghel syndrome: Blepharospasm with oromandibular dystonia, with or without additional features such as torticollis, limb dystonia, or dystonic respiratory patterns [65][66] Iatrogenic Drug-induced movement disorders (including tardive dyskinesia): Repetitive, involuntary movements associated with medications such as antidepressants, antipsychotics, antiepileptics, antimicrobials, and antiarrhythmics [67] Dopaminergic therapy–related effects: Eyelid motor dysfunction secondary to levodopa or apomorphin use, particularly in patients with progressive supranuclear palsy [68] Deep brain stimulation: Induction or exacerbation of eyelid movement abnormalities due to stimulation of the subthalamic nucleus or globus pallidus internus in patients with Parkinson disease [69][70] Genetic Primary dystonia syndromes: Genetic forms of dystonia may include blepharospasm and cervical dystonia. Reported associations include mutations in: Torsin 1A (TOR1A) [71][72][73] G-protein subunit alpha L (GNAL) [74] Anoctamin 3 (ANO3) [75] Tubulin beta 4A (TUBB4A) [76] Zinc finger protein 1 (ZNF1) [71][77] Structural lesions Central nervous system lesions: Vascular, traumatic, or mass lesions involving the midbrain, basal ganglia, thalamus, cerebellum, or motor cortex that disrupt eyelid motor pathways [78] Hemifacial spasm: Unilateral, intermittent contractions of facial muscles, including eyelid closure, typically due to facial nerve irritation Neuromuscular Myasthenia gravis: Fluctuating eyelid ptosis and oculomotor fatigue that worsen with activity and improve with rest; may respond to ice-pack or edrophonium testing [79][80]

Hemifacial spasm: Unilateral, intermittent contractions of facial muscles, including eyelid closure, typically due to facial nerve irritation Neuromuscular Myasthenia gravis: Fluctuating eyelid ptosis and oculomotor fatigue that worsen with activity and improve with rest; may respond to ice-pack or edrophonium testing [79][80] Bell palsy: Unilateral facial weakness with associated symptoms such as retroauricaulr pain, dysgeusia, hyperacusis, hypersalivation, and decreased lacrimation Movement disorders Parkinson disease: Bradykinesia-related impairment of eyelid opening accompanied by tremor, rigidity, and postural instability [38][39] Progressive supranuclear palsy: Supranuclear gaze palsy with impaired eyelid and ocular movements, often associated with early postural instability and falls [81] Focal, segmental, or generalized dystonia: Hyperkinetic movement disorders that may include blepharospasm and impaired eyelid coordination Tardive dyskinesia: Drug-induced hyperkinetic movements that may involve the eyelids and mimic ALO [82] Mechanical Ptosis: Drooping of the upper eyelid due to myogenic, neurogenic, mechanical, or traumatic causes; distinguished by impaired eyelid elevation rather than difficulty initiating the movement [83] Functional and physiologic mimics Functional eyelid disorders: Apparent inability to open the eyes without identifiable structural or neurologic pathology, often associated with psychological factors [25] Voluntary nystagmus: Rapid, voluntary oscillatory eye movements that may interfere with sustained eyelid opening [84] Orbicularis oculi fatigue: Transient difficulty opening the eyes following prolonged voluntary eyelid closure due to muscle fatigue [19] Table Table 9. Differential Diagnosis of Apraxia of Lid Opening. ANO3, anoctamin 3; CNS, central nervous system; GNAL, G-protein subunit alpha L; MRI, magnetic resonance imaging; PSP, progressive supranuclear palsy; TOR1A, torsin 1A; TUBB4A, tubulin beta 4A; ZNF1, zinc finger protein 1

Although ALO is a relatively rare disorder, several clinical studies and case series have investigated its pathophysiology and treatment strategies (see Table 10). Most evidence comes from observational studies and small clinical trials, particularly those evaluating the efficacy of botulinum toxin injections, dopaminergic therapy, and surgical interventions.[55] Early clinical observations demonstrated that ALO often occurs in association with blepharospasm and extrapyramidal disorders, including Parkinson disease and progressive supranuclear palsy. These findings suggested that dysfunction within the basal ganglia–frontal cortical network plays a central role in the disease mechanism. Electromyographic studies further showed abnormal co-contraction of the levator palpebrae superioris and orbicularis oculi muscles, supporting the hypothesis that impaired reciprocal inhibition contributes to difficulty initiating eyelid opening.[85] Several studies have evaluated botulinum toxin type A injections as a therapeutic strategy for ALO, particularly when it coexists with blepharospasm. In a clinical study of patients with focal eyelid dystonia, approximately 83% experienced improvement in eyelid opening after botulinum toxin injections, supporting its role as the primary symptomatic treatment.[86] Further electrophysiological investigations demonstrated that botulinum toxin therapy reduces abnormal orbicularis oculi activity and improves eyelid opening latency, confirming its beneficial neuromuscular effects.[87][88] Despite these promising results, some patients show partial or poor response to botulinum toxin therapy, particularly when ALO occurs as an independent motor initiation disorder rather than a component of blepharospasm. In such cases, adjunctive therapies including levator aponeurosis repair, orbicularis myectomy, or frontalis suspension surgery may be required. Surgical studies have demonstrated long-term improvement in patients with refractory ALO associated with dystonic eyelid disorders.[89] Recent literature continues to explore optimized injection techniques and treatment protocols for isolated ALO. Contemporary case reports and clinical reviews suggest that targeted botulinum toxin administration and multidisciplinary management strategies can significantly improve patient outcomes and functional visual ability.[90]

Despite these promising results, some patients show partial or poor response to botulinum toxin therapy, particularly when ALO occurs as an independent motor initiation disorder rather than a component of blepharospasm. In such cases, adjunctive therapies including levator aponeurosis repair, orbicularis myectomy, or frontalis suspension surgery may be required. Surgical studies have demonstrated long-term improvement in patients with refractory ALO associated with dystonic eyelid disorders.[89] Recent literature continues to explore optimized injection techniques and treatment protocols for isolated ALO. Contemporary case reports and clinical reviews suggest that targeted botulinum toxin administration and multidisciplinary management strategies can significantly improve patient outcomes and functional visual ability.[90] Because ALO is rare, large randomized controlled trials are limited. Current research focuses primarily on improving treatment protocols for dystonia-related eyelid disorders, which may indirectly benefit patients with ALO. Future studies investigating neurophysiological mechanisms, advanced imaging, and neuromodulation therapies may provide further insights into disease pathogenesis and management.[15] Table Table 10. Key Clinical Studies on Apraxia of Lid Opening.

ALO currently lacks a standardized staging system. Nevertheless, clinicians frequently classify the condition based on clinical severity, functional impairment, and associated neurological features (see Table 13). This functional staging provides a practical framework for evaluating disease severity, monitoring progression, and selecting appropriate therapeutic strategies (see Image. Functional Staging of Apraxia of Lid Opening).[91] In the early stages of ALO, patients experience intermittent difficulty initiating eyelid opening, often triggered by fatigue, stress, or prolonged visual tasks. Symptoms may occur sporadically and are typically relieved with sensory tricks (geste antagoniste) or brief manual assistance.[6] As the disorder progresses, patients may develop persistent difficulty opening the eyelids following voluntary closure or blinking. Compensatory mechanisms such as excessive contraction of the frontalis muscle, facial grimacing, or head movements may become more prominent. At this stage, symptoms may interfere with activities such as reading, watching television, or driving. In advanced stages, patients may experience frequent episodes of functional eyelid closure, resulting in temporary visual disability despite preserved ocular structure and muscle strength.[13] This stage is often associated with underlying neurological disorders, including Parkinson disease or dystonic syndromes, and may require more aggressive interventions such as botulinum toxin injections or surgical treatment. Table Table 13. Functional Staging of Apraxia of Lid Opening.

The prognosis for individuals with ALO can vary widely and depends on the chronicity, underlying etiology, associated conditions, and responsiveness to first-line treatment. Because ALO is not itself a degenerative disorder, its prognosis is primarily related to management effectiveness and the disease course of any underlying neurological disorders.[61] ALO may be challenging to treat in many cases. In general, responsiveness to treatment is a good prognostic factor regarding morbidity. Chronicity and resistance to treatment can lead to more disruption in functional independence and disability. In cases where ALO is associated with treatable conditions, such as blepharospasm or Parkinson disease, the use of botulinum toxin injections or dopaminergic medications, respectively, can offer significant symptomatic relief, leading to a relatively good prognosis. For some patients, these treatments can substantially improve their quality of life and may be effective for long periods.[95] However, if ALO is part of a more complex or progressive neurological disorder, such as progressive supranuclear palsy or certain forms of Parkinsonism, the overall prognosis may be more guarded. In these situations, ALO may persist or progress in line with the underlying disease, and management may become more challenging over time. Surgical interventions, such as levator resection or frontalis suspension, may offer a more permanent solution for some patients. However, outcomes can vary, and surgical intervention carries risks of complications and the potential need for further surgery.[96] Despite diverse interventions, ALO often presents a significant therapeutic challenge, and patients may experience only partial improvement. The condition can profoundly impact quality of life, as affected individuals may find routine activities that require unobstructed vision challenging. Generally, ALO itself does not directly affect lifespan, but the functional impairment can significantly impact a person's daily activities and psychosocial well-being. Early recognition and appropriate treatment are vital to improving the prognosis and quality of life for those affected by ALO. Interdisciplinary care involving neurologists, ophthalmologists, and physical therapists is often required to optimize management and provide comprehensive care.[97]

Complications of ALO may arise from both the underlying disorder and its treatment, as well as from the functional consequences of impaired eyelid opening (see Table 14). Beyond the commonly reported transient adverse effects of botulinum toxin therapy, which are typically mild and self-limited, several additional complications may arise in patients with ALO.[98][99][100] These complications may result from underlying neurological dysfunction, secondary ocular surface problems, or long-term functional disability caused by impaired eyelid opening.[6] One important complication is visual disability, including functional blindness. In severe cases, patients may be unable to keep their eyelids open long enough to sustain visual fixation, resulting in episodes of temporary visual deprivation. This phenomenon may significantly hinder activities that require continuous visual attention, such as walking in crowded environments, driving, or reading. In addition, if the upper field of vision is obstructed by an inability to fully lift the eyelids, patients may develop significant visual field impairment and experience difficulties with spatial orientation and mobility. Over time, this functional visual limitation may contribute to reduced independence and increased fall risk, particularly among older adults.[15] Secondary ocular surface disease may also develop. Patients with ALO may exhibit irregular blinking patterns or incomplete eyelid opening, which can disrupt normal tear-film distribution. This disruption may predispose individuals to keratoconjunctivitis sicca (dry eye disease), punctate epithelial erosions, exposure keratopathy, and recurrent corneal epithelial defects.[101] Chronic ocular surface irritation may further exacerbate reflex blinking or eyelid spasms, creating a self-perpetuating cycle that worsens the clinical condition.[18] Another complication involves postural and compensatory muscular strain. Patients frequently adopt compensatory maneuvers to overcome the difficulty opening the eyelids, such as excessive contraction of the frontalis muscle, tilting the head backward, or manually lifting the eyelids. Persistent use of these strategies can lead to forehead muscle fatigue, neck strain, and tension headaches.[29]

Another complication involves postural and compensatory muscular strain. Patients frequently adopt compensatory maneuvers to overcome the difficulty opening the eyelids, such as excessive contraction of the frontalis muscle, tilting the head backward, or manually lifting the eyelids. Persistent use of these strategies can lead to forehead muscle fatigue, neck strain, and tension headaches.[29] ALO may also contribute to psychological distress and reduced quality of life. The chronic nature of the condition, coupled with visible facial abnormalities, can result in embarrassment, social withdrawal, and reduced self-confidence.[102] Studies evaluating dystonia-related eyelid disorders have shown increased rates of anxiety, depression, and social isolation, particularly when symptoms interfere with occupational activities.[8] Functional impairment related to difficulty performing daily tasks may further compound these psychosocial effects, reinforcing the burden of disease. In patients with neurodegenerative disorders such as Parkinson disease or progressive supranuclear palsy, ALO may represent a marker of disease progression. The presence of ALO can complicate neurological rehabilitation and worsen overall motor disability.[51] In addition, the stress of managing ALO can potentially exacerbate other symptoms of the underlying neurologic disorder. Another potential complication is treatment resistance or symptom recurrence. Some patients may develop reduced responsiveness to repeated botulinum toxin injections due to antibody formation or disease progression, leading to persistent eyelid dysfunction. In such cases, alternative management strategies, including surgical interventions, may become necessary, which can further increase morbidity.[103] Surgical interventions carry risks including infection, scarring, and the need for repeat surgeries.[90] Finally, long-standing cases of ALO may increase the risk of accidents or injuries due to intermittent visual obstruction. Patients may experience difficulty navigating unfamiliar environments, climbing stairs, or driving, which can increase their risk of falls and other safety hazards.[104] Early recognition and appropriate multidisciplinary management, including ophthalmologic care, neurological evaluation, and psychological support, are essential to minimize these complications and improve patient outcomes.[6][105] Table

Finally, long-standing cases of ALO may increase the risk of accidents or injuries due to intermittent visual obstruction. Patients may experience difficulty navigating unfamiliar environments, climbing stairs, or driving, which can increase their risk of falls and other safety hazards.[104] Early recognition and appropriate multidisciplinary management, including ophthalmologic care, neurological evaluation, and psychological support, are essential to minimize these complications and improve patient outcomes.[6][105] Table Table 14. Complications of Apraxia of Lid Opening. PSP, progressive supranuclear palsy

Consultations with various specialists may be necessary to manage ALO and ensure comprehensive care. The interdisciplinary team members may include the following: Neurologist: A neurologist can help diagnose ALO, primarily as it may be associated with other neurological conditions such as Parkinson disease, dystonia, or progressive supranuclear palsy. Neurologists can also assist in managing the neurological aspects of the condition and any comorbidities.[81] Ophthalmologist: An ophthalmologist, particularly one specializing in neuro-ophthalmology, can evaluate the structural health of the eyes and eyelids, rule out primary ocular causes of eyelid dysfunction, and participate in the management of ALO, including botulinum toxin injections if indicated.[109] Movement disorder specialist: If the patient has an underlying movement disorder, a movement disorder specialist can provide targeted treatment and management strategies.[110] Occupational therapist: An occupational therapist can assist with adaptations to daily living activities and suggest devices or strategies to compensate for any visual limitations caused by ALO.[111] Physical therapist: Physical therapy may be beneficial for patients who require eyelid-strengthening exercises or other modalities to improve eyelid motor control.[112] Plastic or reconstructive surgeon: If surgical intervention is considered, a consultation with a plastic surgeon or an oculoplastic surgeon experienced in eyelid surgery may be necessary.[113] Psychologist or psychiatrist: Due to the potential psychological impact of ALO, such as anxiety or depression, mental health support from a psychologist or psychiatrist may be necessary. Rehabilitation medicine specialist: This specialist can oversee a comprehensive postoperative rehabilitation program or as part of the long-term management of ALO. An interdisciplinary approach involving these specialists can help formulate a holistic treatment plan tailored to the patient’s specific needs. Personalized, collaborative care can greatly improve the overall prognosis and quality of life for individuals with ALO.

Deterrence and patient education are essential components in managing ALO. Patient education should include the following: Understanding of ALO: Patients should be provided with clear information about ALO, its symptoms, and how it differs from other eyelid disorders. Establishing this foundation helps in setting realistic expectations about the condition and its management.[15] Clinicians should also explain that ALO may be associated with an underlying disorder which may require additional evaluation and treatment, such as Parkinson disease, Huntington disease, myasthenia gravis, Sjögren syndrome, or multiple sclerosis.[61] Treatment options: Patients should be educated about the available treatment modalities, including nonpharmacological approaches, pharmacological treatments, botulinum toxin injections, and possible surgical interventions. Clinicians should explain the benefits, risks, and expected outcomes of each option.[114] Self-help techniques: Patients may require strategies to assist with lid opening, such as using sensory tricks (eg, lightly touching the forehead or temples), maintaining good eyelid hygiene, and performing prescribed eyelid exercises. Medication adherence: The importance of adhering to medication regimens, if prescribed, and the potential adverse effects and importance of reporting them to the healthcare professional, should be discussed. Monitoring: Patients should be encouraged to monitor their symptoms regularly and keep a symptom diary, which can help them manage the condition and inform adjustments to treatment plans. Lifestyle modifications: Clinicians should discuss strategies to help manage symptoms, such as stress-reduction techniques, optimizing sleep, and avoiding activities that may exacerbate them. Regular follow-up: The importance of follow-up appointments to monitor the condition, assess treatment effectiveness, and make necessary adjustments should be emphasized.[115] Support networks: Patients should be informed about support groups or resources for individuals with ALO or associated conditions. Emotional and psychological support can be crucial for coping with chronic conditions. Complications: Patients need information about the potential complications of ALO, such as social and psychological impacts, and the importance of seeking help if they experience these issues.

Support networks: Patients should be informed about support groups or resources for individuals with ALO or associated conditions. Emotional and psychological support can be crucial for coping with chronic conditions. Complications: Patients need information about the potential complications of ALO, such as social and psychological impacts, and the importance of seeking help if they experience these issues. Prognosis: Information should be provided about the prognosis of ALO, including factors that can influence the condition's progression and management strategies that may improve functional outcomes.[116] Effective patient education can empower individuals with ALO to actively participate in their care, help them better manage their condition, and improve their overall quality of life.

Pertinent take-home points regarding ALO include the following: Summary ALO is a nonmotor abnormality characterized by bilateral difficulty with eyelid elevation. This symptom commonly occurs after the patient voluntarily closes their eyes. ALO is a misnomer, given that the condition rarely involves pure and true apraxia. The condition is associated with dysfunction in the corticothalamic, basal ganglia, and focal cranial nerve circuitry. Structures involved include sensorimotor cortical regions, substantia nigra pars reticulata, and brainstem motor nuclei.[117] The most common etiology of ALO is idiopathic focal dystonia. Other causes include blepharospasm or focal dystonia of the eyelids, toxic exposure, face or eyebrow ptosis, dermatochalasis, fatigue, and infectious,  autoimmune, neurodegenerative, neuromuscular, traumatic, iatrogenic, and psychogenic disorders. Patients typically demonstrate compensatory behaviors, including thrusting the head backward, manually opening the eyelids with their fingers, and rubbing the eyebrows. Botulinum toxin A is considered the first-line treatment.[85] Several disorders will present similarly to ALO and must be excluded to treat them appropriately. The prognosis depends on the chronicity, etiology, and responsiveness to the first-line treatment. Chronicity and resistance to treatment can lead to more disruption in functional independence and disability.[15] Pearls Early recognition: ALO is often under-recognized. Awareness of the condition among healthcare professionals is crucial for early diagnosis and management, which can significantly improve the quality of life for affected patients. Multidisciplinary approach: Effective management of ALO often requires a team that includes neurologists, ophthalmologists, and sometimes neurosurgeons, as well as nurses and physical and occupational therapists. Customized treatment: Treatment should be tailored to the individual, as ALO can present differently in each patient, and response to treatment can vary widely. Potential for improvement: While challenging, ALO can often be effectively managed with treatment, including botulinum toxin A injections, physical therapy, and, in some cases, surgical intervention.

Customized treatment: Treatment should be tailored to the individual, as ALO can present differently in each patient, and response to treatment can vary widely. Potential for improvement: While challenging, ALO can often be effectively managed with treatment, including botulinum toxin A injections, physical therapy, and, in some cases, surgical intervention. Disposition: Patients with ALO should have a clear management plan, including regular follow-up appointments to monitor their condition and treatment response. Patients should also be provided with information on how to seek urgent care if they experience significant changes or complications related to their condition.[118] Pitfalls Misdiagnosis: ALO can be mistaken for other conditions, such as blepharospasm or myasthenia gravis, leading to inappropriate treatments. Overlooking underlying conditions: Clinicians must be careful not to miss an underlying neurological disorder associated with ALO, as such a lapse can affect treatment and prognosis. One-size-fits-all approach: Given the variability in presentation and treatment response, a standardized approach may not be effective. Prevention: While studies have not yet identified specific measures to prevent ALO, given its association with other neurological conditions, understanding the risk factors and early signs can help with prompt diagnosis and management.[119] Additional Information Patient education: Patients should be educated about the nature of ALO and the importance of adherence to treatment and follow-up schedules. Research advances: Clinicians must keep abreast of new research, as understanding of ALO and its treatment continues to evolve. Quality of life: Attention should be paid to ALO's impact on a patient's psychological and social well-being, with appropriate support provided.[120] Clinicians must address both the physical aspects of the condition and the broader impacts on the patient's life.

Enhancing healthcare team outcomes for patients with ALO requires a coordinated, interprofessional approach that integrates the skills and expertise of various healthcare providers to ensure comprehensive, patient-centered care. The outcomes of ALO primarily depend on its underlying cause. However, prompt consultation with an interprofessional group of specialists is recommended to improve outcomes regardless of etiology. Shared decision-making and communication are essential elements for positive outcomes. In conjunction with occupational therapists, the neurologist plays an integral part in the diagnosis and treatment. Botulinum toxin injections are usually performed by an ophthalmologist, oculoplastic surgeon, or plastic surgeon; however, they can occasionally be administered by a neurologist or movement disorder specialist. Social worker and case management evaluation may be required, particularly for refractory cases, as ALO can impair the patient's activities of daily living and job performance.[61] Considerations for the interprofessional team include the following: Skills and Strategy Assessment skills: All team members should be skilled in assessing ALO, recognizing its signs, and distinguishing it from other conditions. Treatment planning: Clinicians should develop the best treatment plan, considering both nonpharmacological and pharmacological options, and tailor it to the individual patient’s needs. Surgical consideration: If surgery is indicated, surgeons must possess the technical skills to perform procedures that benefit ALO patients, such as eyelid crutches or levator resection.[121] Ethics and Responsibilities Informed consent: The healthcare team is responsible for ensuring patients understand the benefits and risks of any proposed treatment. Patient autonomy: Patients should be involved in their care decisions, and the team should support their independence and choices. Privacy and confidentiality: Team members must maintain patient confidentiality and share health information only among the care team as necessary for patient treatment.[122] Interprofessional Communication Care coordination: Effective communication among neurologists, ophthalmologists, physical therapists, nurses, and primary care physicians is essential to coordinate care and manage treatments.

Privacy and confidentiality: Team members must maintain patient confidentiality and share health information only among the care team as necessary for patient treatment.[122] Interprofessional Communication Care coordination: Effective communication among neurologists, ophthalmologists, physical therapists, nurses, and primary care physicians is essential to coordinate care and manage treatments. Documentation: Accurate and thorough documentation in a shared electronic health record allows all team members to access patient information, track progress, and adjust treatment plans as needed.[123] Care Coordination Role clarification: Each team member should understand their role in managing ALO to avoid duplication of efforts and to ensure that all aspects of care are addressed. Follow-up: Coordinating follow-up appointments and ongoing care management is essential to monitor treatment effectiveness and adjust interventions as needed. Patient education: Team members should provide consistent, clear education to the patient and their family about ALO, including information regarding treatment options and self-help strategies.[124] Outcomes and Patient Safety Monitoring for adverse events: Close monitoring of treatment-related adverse events, such as those associated with botulinum toxin, is crucial for patient safety. Outcome measurement: The team should use validated tools to measure patient outcomes and assess the impact of treatment on quality of life and functional status. Team Performance Regular team meetings: Interprofessional team meetings can help discuss patient progress, identify issues, and plan future interventions. Continuing education: All team members should engage in continuing education to stay up to date with the latest evidence-based practices for ALO.[125] By fostering an environment of mutual respect and open communication, the healthcare team can enhance care for patients with ALO, thereby improving outcomes, patient satisfaction, and team performance. Each member’s contribution is vital, from diagnosis and treatment to patient education and support.